A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

被引：0
|
作者：
Hamilton, E. P. [1 ]
Bagegni, N. A. [2 ]
Beck, J. T. [3 ]
Cultrera, J. L. [4 ]
Dosunmu, O. [5 ]
Gwin, W. R. [6 ]
Heeke, A. L. [7 ]
Khoury, K. [8 ]
Sellami, D. [9 ]
Shastry, M. [10 ]
Sternberg, D. W. [11 ]
Toppmeyer, D. [12 ]
Wright-Browne, V. M. [13 ]
Yuan, Y. [14 ]
机构：
[1] Sarah Cannon Res Inst Canc Ctr, Drug Dev Unit, Nashville, TN USA
[2] Ctr Adv Med, Siteman Canc Ctr, St Louis, MO USA
[3] Highlands Oncol, Med Oncol, Springdale, AR USA
[4] Florida Canc Specialists North, Villages Canc Ctr, The Villages, FL USA
[5] Sarah Cannon Res Inst, Dev Innovat, Nashville, TN USA
[6] Canc Vaccine Inst Univ Washington, Med, Seattle, WA USA
[7] Levine Canc Inst Morehead, Breast & Surg Oncol, Charlotte, NC USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, ONeal Comprehens Canc Ctr 8, Birmingham, AL USA
[9] Daiichi Sankyo Inc, Oncol Dept, Basking Ridge, NJ USA
[10] Sarah Cannon Res Inst, Strateg Dev Dept, Nashville, TN USA
[11] Daiichi Sankyo Inc, Oncol R&D, Basking Ridge, NJ USA
[12] Rutgers Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA
[13] Florida Canc Specialists, Port Charlotte, FL USA
[14] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204TiP
引用
收藏
页码：S220 / S220
页数：1
相关论文
共 50 条
  • [21] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Gemcitabine plus epirubicin plus taxol (GET) in metastatic breast cancer (MBC) patients (pts): A multicenter phase II study.
    Donati, S
    Gennari, A
    Conte, PF
    Cetto, GL
    Molino, A
    Crino, L
    Mazzoni, F
    Galligioni, E
    Mansutti, M
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [23] Frontline docetaxel (T) capecitabine M combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study.
    Chun, JH
    Lee, HG
    Lee, ES
    Kim, E
    Oh, JH
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 71S - 71S
  • [24] HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
    Yu, Helena A.
    Yang, James Chih-Hsin
    Hayashi, Hidetoshi
    Goto, Yasushi
    Felip, Enriqueta
    Reck, Martin
    Vigliotti, Michele
    Dong, Qian
    Cantero, Frederique
    Fan, Pang-Dian
    Kanai, Masayuki
    Sternberg, David W.
    Jaenne, Pasi A.
    FUTURE ONCOLOGY, 2023, 19 (19) : 1319 - 1329
  • [25] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [26] Phase II trial of weekly docetaxel (DOC) and prolonged capecitabine (C) in metastatic breast cancer (MBC) patients (pts).
    Shapiro, CL
    Ramaswamy, B
    Rhoades, C
    Kendra, K
    Allen, J
    Hauger, M
    Loughlin, H
    Moore, T
    Villalona, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S203
  • [27] Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results
    Brufsky, A
    Orlando, M
    Fox, K
    Jame, A
    Katherine, T
    Franco, S
    Vincent, H
    Terry, E
    LaTrice, H
    Steven, S
    Allen, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [28] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [29] Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
    Schaller, G
    Bangemann, N
    Gonsch, T
    Weber, J
    Kleine-Tebbe, A
    Conrad, B
    Klare, P
    Hindenburg, HJ
    Ruhmland, B
    Lakner, V
    Hinke, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S95
  • [30] Prediction of brain relapse (BR) in HER-2 positive metastatic breast cancer (MBC) patients (pts)
    Duchnowska, R.
    Czartoryska-Arlukowicz, B.
    Radecka, B.
    Szostakiewicz, B.
    Sosinska, K.
    Karpinska, A.
    Dziadziuszko, R.
    Staroslawska, E.
    Kubiatowski, T.
    Sczylik, C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 213 - 213
12345